Calcimimetics in CKD - Results from recent clinical studies

Pediatric Nephrology

Volumn 23, Issue 10, 2008, Pages 1721-1728

  Schlieper, Georg ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Calcimimetics; Chronic kidney disease; Cinacalcet; End stage renal disease; Pediatric patients; Review; Secondary hyperparathyroidism

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CINACALCET; CYCLOSPORIN; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; TACROLIMUS; VITAMIN D; VITAMIN D DERIVATIVE;

ANOREXIA; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CORONARY ARTERY OBSTRUCTION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG USE; EDITORIAL; FEASIBILITY STUDY; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPOPHOSPHATASIA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UREMIA; VOMITING;

CHRONIC DISEASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NAPHTHALENES; RENAL DIALYSIS;

EID: 51549121765     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-008-0900-4     Document Type: Editorial

References (33)

1. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254
2. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575-583
3. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525
4. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW (2005) Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16:800-807
5. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC (2006) Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 47:715-726
6. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186-2193
7. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760-771
8. Messa P, Macario F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazao JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F (2008) The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3:36-45
9. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S (2008) Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23:328-335
10. Vervloet M, Malberti F, Ashman N, Rix M, Ureña P, Fouque D, Baños A, Harris C, Zani W, Neyer U (2007) Cinacalcet (Mimpara/ Sensipar) increased KDOQI goal achievement in "real-world" clinical practice (ECHO study). In: Renal Week 2007 (American Society of Nephrology Annual Meeting). Abstract SU-FC098. San Francisco
11. Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, Bushinsky DA (2008) Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant doi: 10.1093/ndt/gfn026
12. Fishbane S, Wetmore J, Moustafa M, Martinez C, Ling X, Turner S, Charytan C (2007) Treatment with cinacalcet HCl and concurrent low-dose vitamin D improved management of secondary hyperparathyroidism (SHPT) compared with vitamin D alone. In: Renal Week 2007 (American Society of Nephrology Annual Meeting). Abstract SU-FC100. San Francisco
13. Diez JJ, Miguel JL, Codoceo R, Iglesias P, Bajo MA, Sanchez C, Del Peso G, Gil F, Martinez-Ara J, Gancedo PG, Selgas R (2008) Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. Nephrol Dial Transplant 23:1387-1395
14. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793-1800
15. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P (2007) Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): Rationale and design overview. Clin J Am Soc Nephrol 2:898-905
16. Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K (2008) Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol doi: 10.1007/s00467-007-0742-5
17. Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D (2008) Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol doi: 10.1007/s00467-008-0810-5
18. Nakagawa K, Perez EC, Oh J, Santos F, Geldyyev A, Gross ML, Schaefer F, Schmitt CP (2008) Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia. Nephrol Dial Transplant doi: 10.1093/ndt/gfn143
19. U.S.National Library of Medicine 8RPBM2IoHH&HS (2008) Daily med current medication Information on cinacalcet. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfocfm?id=6922
20. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V (2005) Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46:58-67
21. Chonchol M, Locatelli F, Abboud H, Charytan C, de Francisco A, Jolly S, Kaplan M, Roger S, Sarkar S, Albizem M, Cheng S, Kubo Y, Block G (2007) A randomized, double-blind, placebo-controlled study of cinacalcet in CKD not on dialysis. In: Renal Week 2007 (American Society of Nephrology Annual Meeting). Abstract SA-PO867. San Francisco
22. Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, Schwarz A (2005) Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Transplant 5:1934-1941
23. Chonchol M, Wüthrich RP (2008) Potential future uses of calcimimetics in patients with chronic kidney disease. Nephrol Dial Transplant plus 1:i36-i41
24. Falck P, Vethe NT, Asberg A, Midtvedt K, Bergan S, Reubsaet JL, Holdaas H (2008) Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 23:1048-1053
25. Bilezikian JP, Silverberg SJ (2004) Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350:1746-1751
26. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
27. Iglesias P, Ais G, Gonzalez A, Tajada P, Arevalo CG, Pardo EF, Diez JJ (2008) Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci 335:111-114
28. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, Schwanauer LE, Olson KA, Klassen P, Bilezikian JP (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92:3803-3808
29. Chakrabarty S, Wang H, Canaff L, Hendy GN, Appelman H, Varani J (2005) Calcium sensing receptor in human colon carcinoma: Interaction with Ca(2+) and 1,25-dihydroxyvitamin D(3). Cancer Res 65:493-498
30. Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, Roepke TK, Deichstetter M, Prinz C, Cheng SX, Martin D, Hebert SC (2006) Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Natl Acad Sci USA 103:9390-9397
31. Ogata H, Ritz E, Odoni G, Amann K, Orth SR (2003) Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14:959-967
32. Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, Schaefer F, Schmitt CP (2006) Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 17:655-662
33. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML (2008) Calcimimetic R-568 or calcitriol: Equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294:F748-F757